Company Overview of Autifony Therapeutics Limited
Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.
90 High Holborn
London, WC1V 6XX
Founded in 2011
Key Executives for Autifony Therapeutics Limited
Co-Founder and Head of Preclinical Drug Discovery
Compensation as of Fiscal Year 2014.
Autifony Therapeutics Limited Key Developments
Autifony Therapeutics Recruits First Trial Patient
Apr 27 15
Imperial Innovations Group plc announced that portfolio company Autifony Therapeutics (Autifony or the Company) has announced that it has recruited the first subject in a Phase IIa study for treatment of age-related hearing loss. This study (called CLARITY-1) will explore the potential of Autifony's lead product AUT00063, to improve hearing in the elderly by focusing on the discrimination of speech from background noise. The study will be conducted in around 14 key sites across the USA. Age-related hearing loss is an area of significant unmet medical need affecting up to half of people over the age of 65. For some the onset can occur well before that time; with the UK charity Action on Hearing Loss estimating that 40% of over 50 year olds have some form of hearing loss. The key complaint for those suffering from age-related hearing loss is difficulty understanding speech, in particular in noisy environments, or where several people are talking at the same time, such as at social gatherings. There are no current treatment options and whilst hearing aids or cochlear implants can help some sufferers, interpreting speech remains a challenge. AUT00063 is a novel, first-in-class Kv3 potassium channel modulator and is also in development for the treatment of tinnitus, with a Phase IIa clinical trial in this indication already underway in the UK.
Autifony Therapeutics Announces Initiation of Phase IIa Study for First-In-Class Drug to Treat Tinnitus
Nov 20 14
Autifony Therapeutics Limited has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In Eliminating Tinnitus) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to reduce the symptoms of tinnitus, which is an area of significant unmet medical need. In the earlier Phase I study, AUT00063 showed a good safety and tolerability profile, and pharmacokinetics compatible with once daily oral dosing. The Phase IIa study will focus in particular on tinnitus associated with hearing loss following noise exposure or ageing. Subjects will undergo four weeks of once daily dosing. In the earlier Phase I study, AUT00063 showed a good safety and tolerability profile, and pharmacokinetics compatible with once daily oral dosing. The Phase IIa study will focus in particular on tinnitus associated with hearing loss following noise exposure or ageing. Subjects will undergo four weeks of once daily dosing. AUT00063 is also in development for the treatment of age-related hearing loss and a Phase IIa clinical trial in this indication is expected to start soon in the US.
Autifony Therapeutics Collaborates with University of Manchester and Newcastle University to Develop First-in-Class Treatment for Schizophrenia
Jul 2 13
Imperial Innovations Group plc announced that its portfolio company, Autifony Therapeutics is collaborating with research groups at the University of Manchester and Newcastle University to develop a first-in-class treatment for schizophrenia. The £2.75 million research collaboration is part-funded by the Biomedical Catalyst which awarded a £1.9 million grant to Autifony and the two Universities. The funding will enable selection and progression of a compound from a group of potential candidates through to application to conduct clinical trials. Schizophrenia is a serious psychiatric illness that has a high unmet need and imposes a huge social and economic burden. Research into schizophrenia has seen diminishing investment in recent years, with existing schizophrenia treatments demonstrating poor efficacy and considerable side effects for many patients. Autifony recently initiated a Phase I clinical study, expected to complete in the first quarter of 2014, as part of its lead programme to develop first-in-class drugs for hearing loss and tinnitus.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries